CO2020005116A2 - Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr - Google Patents
Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attrInfo
- Publication number
- CO2020005116A2 CO2020005116A2 CONC2020/0005116A CO2020005116A CO2020005116A2 CO 2020005116 A2 CO2020005116 A2 CO 2020005116A2 CO 2020005116 A CO2020005116 A CO 2020005116A CO 2020005116 A2 CO2020005116 A2 CO 2020005116A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- compositions
- treatment
- ttr gene
- gene editing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 101150091380 TTR gene Proteins 0.000 title abstract 2
- 206010002022 amyloidosis Diseases 0.000 title abstract 2
- 238000010362 genome editing Methods 0.000 title 1
- 102100029290 Transthyretin Human genes 0.000 abstract 2
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 abstract 1
- 108010071690 Prealbumin Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Manufacturing & Machinery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
RESUMEN Se proporcionan las composiciones y los métodos para editar, por ejemplo, introducir ruptura bicatenaria, dentro del gen TTR. Se proporcionan las composiciones y los métodos para tratar sujetos que tienen amiloidosis asociada con la transtiretina (ATTR).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762566236P | 2017-09-29 | 2017-09-29 | |
US201862671902P | 2018-05-15 | 2018-05-15 | |
PCT/US2018/053382 WO2019067872A1 (en) | 2017-09-29 | 2018-09-28 | COMPOSITIONS AND METHODS FOR EDITING THE TTR GENE AND TREATING AMYLOID DOSE ATTR |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020005116A2 true CO2020005116A2 (es) | 2020-05-15 |
Family
ID=63858214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0005116A CO2020005116A2 (es) | 2017-09-29 | 2020-04-24 | Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr |
Country Status (15)
Country | Link |
---|---|
US (3) | US20200248180A1 (es) |
EP (1) | EP3688161A1 (es) |
JP (2) | JP2021500864A (es) |
KR (1) | KR20200058509A (es) |
CN (2) | CN111417728A (es) |
AU (1) | AU2018338787A1 (es) |
BR (1) | BR112020005287A2 (es) |
CA (1) | CA3077251A1 (es) |
CO (1) | CO2020005116A2 (es) |
IL (2) | IL311170A (es) |
MX (1) | MX2020003608A (es) |
PH (1) | PH12020550364A1 (es) |
SG (1) | SG11202002565YA (es) |
TW (1) | TW201932479A (es) |
WO (1) | WO2019067872A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190098879A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use |
WO2020198697A1 (en) * | 2019-03-28 | 2020-10-01 | Intellia Therapeutics, Inc. | Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent |
CA3137761A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
CN115176001A (zh) * | 2019-12-11 | 2022-10-11 | 因特利亚治疗公司 | 用于基因编辑的修饰的引导rna |
EP4237005A1 (en) * | 2020-10-28 | 2023-09-06 | Novo Nordisk A/S | Anti-transthyretin antibodies and methods of use thereof |
TW202237845A (zh) | 2020-12-11 | 2022-10-01 | 美商英特利亞醫療公司 | 用於涉及去胺作用之基因體編輯之多核苷酸、組合物及方法 |
CN112795595A (zh) * | 2020-12-24 | 2021-05-14 | 中山大学 | 一种遗传性转甲状腺素蛋白淀粉样变性疾病的基因治疗系统 |
EP4359531A1 (en) | 2021-06-22 | 2024-05-01 | Intellia Therapeutics, Inc. | Methods for in vivo editing of a liver gene |
WO2023028469A2 (en) * | 2021-08-23 | 2023-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted integration at beta-globin locus in human hematopoietic stem and progenitor cells |
CA3232420A1 (en) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
CN116064598B (zh) * | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
WO2023185697A2 (en) * | 2022-03-29 | 2023-10-05 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of transthyretin amyloidosis |
TW202417017A (zh) * | 2022-06-30 | 2024-05-01 | 香港商正基基因科技有限公司 | 具有化學修飾的導引rna |
WO2024003805A1 (en) * | 2022-06-30 | 2024-01-04 | Geneditbio Limited | Methods and compositions for ttr gene editing and therapy using crispr system |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
AU669353B2 (en) | 1991-12-24 | 1996-06-06 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
EP0760008A1 (en) | 1994-05-19 | 1997-03-05 | Dako A/S | Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis |
US6974667B2 (en) | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
EP2323667A4 (en) | 2008-08-07 | 2012-07-25 | Isis Pharmaceuticals Inc | MODULATION OF TRANSTHYRETIN EXPRESSION BY TREATMENT OF CNS DISEASES |
CN103937793B (zh) | 2008-10-20 | 2017-08-11 | 阿尔尼拉姆医药品有限公司 | 抑制运甲状腺素蛋白表达的组合物和方法 |
EP2496238A4 (en) | 2009-11-03 | 2013-10-02 | Alnylam Pharmaceuticals Inc | FORMULATED LIPID COMPOSITIONS AND METHODS FOR INHIBITING TRANSTHYRETIN EXPRESSION (TTR) |
PT2563920T (pt) | 2010-04-29 | 2017-05-26 | Ionis Pharmaceuticals Inc | Modulação da expressão de transtirretina |
DK3301177T3 (da) | 2011-11-18 | 2020-06-15 | Alnylam Pharmaceuticals Inc | Rnai-midler, sammensætninger og fremgangsmåder til anvendelse deraf til behandling af transthyretin (ttr)-forbundne sygdomme |
US8993233B2 (en) | 2012-12-12 | 2015-03-31 | The Broad Institute Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
ES2658401T3 (es) * | 2012-12-12 | 2018-03-09 | The Broad Institute, Inc. | Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas |
US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
MY170059A (en) | 2012-12-17 | 2019-07-02 | Harvard College | Rna-guided human genome engineering |
EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
RU2676708C2 (ru) * | 2013-04-16 | 2019-01-10 | Регенерон Фармасьютикалс, Инк. | Направленная модификация генома крысы |
EP2992098B1 (en) | 2013-05-01 | 2019-03-27 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating hbv and ttr expression |
DK3011032T3 (da) * | 2013-06-17 | 2020-01-20 | Broad Inst Inc | Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til målretning mod og modellering af sygdomme og forstyrrelser i postmitotiske celler |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
WO2015095340A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
US20170191123A1 (en) | 2014-05-28 | 2017-07-06 | Toolgen Incorporated | Method for Sensitive Detection of Target DNA Using Target-Specific Nuclease |
EP3461885B1 (en) * | 2014-06-26 | 2021-10-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
WO2016010840A1 (en) | 2014-07-16 | 2016-01-21 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
CA2978314A1 (en) | 2015-03-03 | 2016-09-09 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
US10369232B2 (en) * | 2015-09-21 | 2019-08-06 | Arcturus Therapeutics, Inc. | Allele selective gene editing and uses thereof |
HUE055458T2 (hu) | 2015-09-21 | 2021-11-29 | Trilink Biotechnologies Llc | Kompozíciók és módszerek 5'-Cap RNS-ek szintézisére |
EP3371305A1 (en) * | 2015-11-06 | 2018-09-12 | Crispr Therapeutics AG | Materials and methods for treatment of glycogen storage disease type 1a |
JP6932698B2 (ja) | 2015-12-01 | 2021-09-08 | クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG | アルファ1アンチトリプシン欠乏症の治療のための材料および方法 |
WO2017158422A1 (en) | 2016-03-16 | 2017-09-21 | Crispr Therapeutics Ag | Materials and methods for treatment of hereditary haemochromatosis |
WO2017173054A1 (en) * | 2016-03-30 | 2017-10-05 | Intellia Therapeutics, Inc. | Lipid nanoparticle formulations for crispr/cas components |
WO2018007871A1 (en) * | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
WO2018107028A1 (en) | 2016-12-08 | 2018-06-14 | Intellia Therapeutics, Inc. | Modified guide rnas |
-
2018
- 2018-09-28 WO PCT/US2018/053382 patent/WO2019067872A1/en active Application Filing
- 2018-09-28 CN CN201880076628.6A patent/CN111417728A/zh active Pending
- 2018-09-28 CN CN202410646325.0A patent/CN118530993A/zh active Pending
- 2018-09-28 CA CA3077251A patent/CA3077251A1/en active Pending
- 2018-09-28 JP JP2020517500A patent/JP2021500864A/ja active Pending
- 2018-09-28 TW TW107134336A patent/TW201932479A/zh unknown
- 2018-09-28 MX MX2020003608A patent/MX2020003608A/es unknown
- 2018-09-28 AU AU2018338787A patent/AU2018338787A1/en active Pending
- 2018-09-28 BR BR112020005287-6A patent/BR112020005287A2/pt unknown
- 2018-09-28 EP EP18786638.9A patent/EP3688161A1/en active Pending
- 2018-09-28 SG SG11202002565YA patent/SG11202002565YA/en unknown
- 2018-09-28 KR KR1020207012163A patent/KR20200058509A/ko not_active Application Discontinuation
- 2018-09-28 IL IL311170A patent/IL311170A/en unknown
-
2020
- 2020-03-15 IL IL273317A patent/IL273317A/en unknown
- 2020-03-24 US US16/828,573 patent/US20200248180A1/en active Pending
- 2020-03-27 PH PH12020550364A patent/PH12020550364A1/en unknown
- 2020-04-24 CO CONC2020/0005116A patent/CO2020005116A2/es unknown
-
2022
- 2022-12-06 JP JP2022194564A patent/JP2023029966A/ja active Pending
- 2022-12-09 US US18/064,086 patent/US11795460B2/en active Active
- 2022-12-09 US US18/063,972 patent/US11965165B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW201932479A (zh) | 2019-08-16 |
WO2019067872A1 (en) | 2019-04-04 |
US11965165B2 (en) | 2024-04-23 |
IL311170A (en) | 2024-04-01 |
KR20200058509A (ko) | 2020-05-27 |
CA3077251A1 (en) | 2019-04-04 |
CN118530993A (zh) | 2024-08-23 |
US20230257747A1 (en) | 2023-08-17 |
US11795460B2 (en) | 2023-10-24 |
JP2023029966A (ja) | 2023-03-07 |
MX2020003608A (es) | 2020-09-25 |
JP2021500864A (ja) | 2021-01-14 |
BR112020005287A2 (pt) | 2020-09-24 |
SG11202002565YA (en) | 2020-04-29 |
AU2018338787A1 (en) | 2020-04-16 |
US20230118592A1 (en) | 2023-04-20 |
PH12020550364A1 (en) | 2021-02-15 |
US20200248180A1 (en) | 2020-08-06 |
IL273317A (en) | 2020-04-30 |
CN111417728A (zh) | 2020-07-14 |
EP3688161A1 (en) | 2020-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020005116A2 (es) | Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr | |
ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2020002914A1 (es) | Métodos y composiciones para tratar el cáncer | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
CL2019002895A1 (es) | Inhibidores de pd-1/pd-l1. | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CL2018000198A1 (es) | Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr | |
ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
CR20180058A (es) | Nuevos derivados de fenoximetilo | |
CL2019001339A1 (es) | Inhibidores de la magl. | |
CL2019003398A1 (es) | Inhibidores pirazólicos de magl. | |
CL2019001335A1 (es) | Inhibidores de magl. | |
CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
UY36654A (es) | Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen | |
BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares | |
CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
CL2017000178A1 (es) | Compuestos para usar en el tratamiento antihelmíntico | |
CO2022000214A2 (es) | Composiciones para el tratamiento de la pérdida del cabello | |
CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores | |
UY35956A (es) | Formulación de atazanavir y cobicistat para el tratamiento del vih | |
BR112017006190A2 (pt) | agentes terapêuticos humanos |